The 2012 AHS/AAN Guidelines for Prevention of Episodic Migraine: A Summary and Comparison With Other Recent Clinical Practice Guidelines

Graham Headache Center and the Department of Neurology, Division of Headache and Pain, Brigham and Women's and Faulkner Hospitals, Boston, MA, USA.
Headache The Journal of Head and Face Pain (Impact Factor: 3.19). 06/2012; 52(6):930-45. DOI: 10.1111/j.1526-4610.2012.02185.x
Source: PubMed

ABSTRACT Updated guidelines for the preventive treatment of episodic migraine have been issued by the American Headache Society (AHS) and the American Academy of Neurology (AAN). We summarize key 2012 guideline recommendations and changes from previous guidelines. We review the characteristics, methods, consistency, and quality of the AHS/AAN guidelines in comparison with recently issued guidelines from other specialty societies.
To accomplish this, we reviewed the AHS/AAN guidelines and identified comparable recent guidelines through a systematic MEDLINE search. We extracted key data, and summarized and compared the key recommendations and assessed quality using the Appraisal of Guidelines Research and Evaluation-II (AGREE-II) tool. We identified 2 additional recent guidelines for migraine prevention from the Canadian Headache Society and the European Federation of Neurological Societies. All of the guidelines used structured methods to locate evidence and linked recommendations with assessment of the evidence, but they varied in the methods used to derive recommendations from that evidence.
Overall, the 3 guidelines were consistent in their recommendations of treatments for first-line use. All rated topiramate, divalproex/sodium valproate, propranolol, and metoprolol as having the highest level of evidence. In contrast, recommendations diverged substantially for gabapentin and feverfew. The overall quality of the guidelines ranged from 2 to 6 out of 7 on the AGREE-II tool.
The AHS/AAN and Canadian guidelines are recommended for use on the basis of the AGREE-II quality assessment. Recommendations for the future development of clinical practice guidelines in migraine are provided. In particular, efforts should be made to ensure that guidelines are regularly updated and that guideline developers strive to locate and incorporate unpublished clinical trial evidence.

1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Vitamin D deficiency is associated with a number of human disorders, including cardiovascular disease, cancer, diabetes, frailty, and infections. Since an association between vitamin D and migraine has also been recently speculated, we performed an electronic search on Medline, Scopus, and Web of Science using the keywords "migraine" and "vitamin D," "25OH-D" "cholecalciferol," "ergocalciferol," with no language or date restriction. The electronic search allowed identifying seven studies (3 observational, 2 cross-sectional, and 2 case reports). The two case reports, including four women, showed favourable effects of vitamin D supplementation on migraine severity, but these studies were small and not placebo controlled. As regards the three observational studies, vitamin D deficiency was observed in 13.2 to 14.8% of migraine patients, and these rates do not differ from those reported in the general population (i.e., vitamin D deficiency between 22 and 42%). The results of the two cross-sectional studies are even more controversial, since no association was found between vitamin D status and migraine in both trials. In conclusion, the current evidence suggests that the association between migraine and vitamin D lacks reliable scientific support.
    BioMed Research International 05/2014; 2014:827635. DOI:10.1155/2014/827635 · 2.71 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Migraine is a widespread primary headache disorder which requires a broad and an inclusive approach. This requires the use of appropriate pharmacological agents along with the integration of non-pharmacological therapies. There are 2 main categories of medication that are utilized for the treatment of migraine. Acute medications aim to relieve the pain and other symptoms associated with individual attacks and halt progression. Preventive therapies are used to reduce attack frequency, severity, and duration. There are a variety of medications available for both acute and preventive therapies. Some of them are specific for migraine while others are nonspecific headache or pain medications. Specific acute treatment for migraine includes triptans and ergots, which by definition are effective in migraine but not other non-headache pain disorders. Nonsteroidal anti-inflammatory drugs, neuroleptics/antiemetics, barbiturates, antihistamines, and opioids are some of the nonspecific medications that can be utilized for acute treatment. Preventive options for the treatment include beta-blockers, calcium channel blockers, antidepressants, and antiepileptic medications. With preventive and acute therapy, many patients are able to find relief from the debilitating effects of migraine.
    Techniques in Regional Anesthesia [amp ] Pain Management 01/2012; 16(1):19–24. DOI:10.1053/j.trap.2012.11.003
  • [Show abstract] [Hide abstract]
    ABSTRACT: Patients love complementary and alternative treatments! Most colleagues spend a significant amount of time discussing the benefit and the risk of these therapies. Fortunately, there is scientific evidence for or against the efficacy of several such therapeutic approaches. Knowing the evidence helps to facilitate the therapeutic process, especially when dealing with patients with chronic headache. Behavioral approaches, such as cognitive behavior therapy, relaxation techniques, and biofeedback, are supported by evidence (which is partly outdated), but require a significant amount of time. Physiotherapy and aerobic exercise may be effective to treat headaches and interestingly, the latter also seems to work in depression. The evidence for hypnosis is lacking, possibly for methodological reasons. Homeopathy was shown not to be effective in headaches. There is no convincing evidence for the efficacy of spinal manipulation. There is growing evidence that acupuncture is efficacious; however, there seems to be no difference to sham acupuncture. For several vitamins and supplements, as well as herbal remedies, there is evidence from small, randomized controlled trials. A major problem is that traditional and statistically powerful trial designs cannot be applied in quite a number of complementary and alternative treatments. The best way to treat patients with headache is most probably a tailored approach with a combination of both, conventional and complementary treatment, resulting in a multimodal migraine management.
    Techniques in Regional Anesthesia [amp ] Pain Management 01/2012; 16(1):76–81. DOI:10.1053/j.trap.2012.11.011


Available from